• Lexaria Bioscience entered an agreement with an unnamed pharmaceutical company to evaluate DehydraTECH drug-delivery technology using one or more proprietary molecules.
• The agreement marks its third pharmaceutical company relationship, separate from two existing material transfer agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202611040900TNWSWRCACNPR_____1kWVF2O1j) on November 04, 2026, and is solely responsible for the information contained therein.